Image may be NSFW.
Clik here to view.
Clik here to view.
Nuvo Research to release Phase 2 WF10 data in Q1
Nuvo Research (TSX:NRI) plans to release, in the first quarter of 2015, the results of a confirmatory Phase 2 study for a potential blockbuster allergic rhinitis drug, WF10, which could be a...
View Article
Image may be NSFW.
Clik here to view.
Clik here to view.
Nuvo cites placebo effect in WF10 trial
Nuvo Research (TSX:NRI) cited a placebo effect for its WF10 failing to achieve statistical significance in a Phase 2 trial in Germany for the treatment of refractory allergic rhinitis. Each of the...
View Article
Image may be NSFW.
Clik here to view.
Clik here to view.
Nuvo Research outlines strategic plans
Nuvo Research (TSX:NRI) has examined strategic alternatives with a view to increasing shareholder value by obtaining better recognition of its assets. After examining alternative structures and...
View Article
More Pages to Explore .....
